Week in Review: Cellular Biomedicine In-licenses Cancer Immunotherapy from China

Cellular Biomedicine Group, a China-US cell therapy company, acquired CAR-T cancer immunotherapy technology from Beijing's Chinese PLA General Hospital; ACT Genomics of Taipei raised $8 million in a Series A to expand its portfolio of cancer diagnostic tests; NeuroVive of Sweden raised $3.3 million for its Taiwan subsidiary, which it will IPO on the Taipei exchange; the GPCR Consortium, a US-China nonprofit research group, added two new pharma members: Novo Nordisk and Merck; Crown Bioscience, a preclinical CRO with facilities in the US and China, will work with the National Resource Center for Mutant Mice to build experimental immune-oncology mouse models; Response Biomedical of Canada granted Shanghai Elite Biotech an exclusive license to distribute its RAMP® cardiovascular point-of-care tests in China; Hua Medicine announced positive results from a China Phase Ib trial of an oral GKA treatment for patients with type 2 diabetes; and Qiagen's TB test showed the incidence of latent TB infection in China's population is 18.8%, much lower than previous estimates. More details.... Stock Symbols: (NSDQ: CBMG) (STO: NVP) (NYSE: NVO) (NYSE: MRK) (TO: RBM) (NSDQ: QGEN) Share this with colleagues: // //